This guide was developed by AACAP to give reliable information about medication
used to treat bipolar disorder in children and adolescents to parents whose children
have been diagnosed with the illness.
Q5.SCOPING QUESTION: In individuals with psychotic disorders (including schizophrenia) who require long-term antipsychotic treatment, what is the safety and role of depot antipsychotic medication?
Q8. SCOPING QUESTION: In people with bipolar disorders who require maintenance treatment, are a) antipsychotics or b) mood stabilizers (lithium, valproate or carbamazepine) effective and safe?
This Practice Parameter reviews the evidence from research and clinical experience and highlights significant advances in the assessment and treatment of posttraumatic stress disorder since the previous Parameter was published in 1998. It highlights the importance of early identification of posttrau...matic stress disorder, the importance of gathering information from parents and children, and the assessment and treatment of comorbid disorders. It presents evidence to support trauma-focused psychotherapy, medications, and a combination of interventions in a multimodal approach.
Journal of the American Academy of Children & Adolescents Psychiatry, Vol. 49 No. 4 APRIL 2010 pp.414-430
more
Schizophr Bull. 2014 Jan;40(1):192-213. doi: 10.1093/schbul/sbs150. Epub 2012 Dec 17.
World J Meta-Anal. Aug 26, 2017; 5(4): 103-123
Published online Aug 26, 2017. doi: 10.13105/wjma.v5.i4.103
Q7: In individuals with bipolar mania, are a) antipsychotics, b) mood stabilizers (lithium carbonate, valproate, and carbamazepine) effective and safe
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
Q2: In individuals with psychotic disorders (including schizophrenia), is the use of two or more antipsychotic medications concurrently more effective and safer than the use of one antipsychotic only?
Q4: In individuals with long term and/or recurrent psychotic disorders (including schizophrenia), should individuals be maintained on pharmacotherapy indefinitely or withdrawn from treatment in order to allow for the best outcomes?
Q3: In individuals with a first psychotic episode with full remission, how long should antipsychotic drug treatment be continued after remission in order to allow for the best outcomes?
Q1: In individuals with psychotic disorders (including schizophrenia), are antipsychotic drugs safe and effective?
Q6: In individuals with psychotic disorders (including schizophrenia) who require long term antipsychotic treatment, are anticholinergic medications more effective in preventing or reducing extrapyramidal side-effects and/or improving treatment adherence than placebo/treatment as usual?
Accessed January 22, 2019.
This updated version include important research that has added to our knowledge about effective treatments for
child and adolescent depression. Its goal is to help parents and families make informed decisions about getting the best care for a child with depression. For ...easy use, it is presented in Frequently Asked Questions (FAQ) format.
more
Q14. SCOPING QUESTION: In adults with psychotic disorders (including schizophrenia), what is the comparative effectiveness and safety of second-generation antipsychotic medications?
This publication seeks to describe the best treatments and practices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients in accordance with the guidelines and laws o...f their country of practice. Some medications may not be available in some countries and readers should consult the specific drug information since not all the unwanted effects of medications are mentioned.
more
Other disorders
Chapter H.5.1
The guide is organized into the major types of toxicities, the associated symp-toms, possible offending medications, and the suggested nursing assessments and interventions. Some symptoms (e.g. nausea) may be associated with a num-ber of underlying causes and may be mild, or a symptom of... a more serious medical situation requiring urgent attention. The pathophysiology for medica-tion-related fatigue and hypersalivation are unclear and these symptoms are not grouped under a specific type of toxicity. Additional information (comments) are provided for each toxicity to highlight relevant clinical information that may assist in management of side effects. Medications more strongly associated with the side effect appear in bold text. The appendices include tools nurses can use to more thoroughly assess patient complaints of pain, depression and neuropathy.
more